From Years to Months: AI’s Impact on Cancer Drug Discovery With: Tom Neyarapally
Tom Neyarapally explains how Archetype Therapeutics uses AI to revolutionize cancer research by drastically reducing drug discovery timelines. By merging established genomic classifiers—tests that predict cancer outcomes—with cutting-edge generative AI, the company can virtually screen billions of molecules in a single day. This process targets multiple genes simultaneously, identifying compounds most likely to improve patient survival. By eliminating the need to physically test low-probability candidates, this approach saves time, reduces costs, and accelerates the development of life-saving therapies.
Episode Contents:
About the Guest
Tom Neyarapally is CEO of Archetype Therapeutics, pioneering AI-driven cancer screening and drug discovery. Learn more at: https://www.linkedin.com/in/tom-neyarapally-8786b7/
Key Takeaways
- AI-driven screening can reduce cancer R&D timelines from years to months.
- Combining genomic classifiers with generative AI targets multiple cancer genes at once.
- Virtual screening eliminates costly, low-probability physical tests.
Transcript Summary
How does AI speed up cancer treatment R&D?
By merging genomic classifiers with generative AI, billions of molecules can be virtually screened to predict their effect on cancer biology.
Why is this faster than traditional methods?
It avoids physical testing of unlikely candidates, focusing resources on de-risked molecules.
What’s the impact on patient outcomes?
Enables faster identification of therapies for patients with poor prognoses, potentially extending survival.
More Topics
- AI in Patient Care
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
Keep Exploring
About the Series
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine.
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine.
Mika Newton is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and is no stranger to bringing transformative technologies to market and fostering innovation.